The massive authorized share increase and Yorkville SEPA with aggressive anti-dilution provisions signal severe capital needs and likely continued stock pressure. Monitor the Nov 10 vote outcome — if all proposals pass, expect accelerated dilution as the company draws down the remaining $13.35M Yorkville facility. The Nasdaq compliance deadline in Feb 2027 adds governance risk; failure to appoint an independent director could trigger delisting proceedings.
Price Chart
Executive Summary
Health In Tech's 2026 proxy statement seeks shareholder approval for five proposals, including a massive authorized share increase from 220M to 720M shares, a standby equity purchase agreement with Yorkville allowing up to $20M in stock sales with heavy dilution potential, and a 10M share increase to the equity incentive plan. The filing reveals the company is out of compliance with Nasdaq's majority independent board and three-member audit committee requirements following a director resignation, with a cure period expiring February 2027. CEO Tim Johnson received $814,880 in total compensation for 2025, while CFO Julia Qian received $730,240, both heavily weighted toward stock awards.
Key Facts
- Proposal to increase authorized shares from 220M to 720M (500M new Class A shares), a 227% increase
- SEPA with Yorkville allows up to $20M in stock sales at 97% of lowest 3-day VWAP, with $6.65M already drawn via convertible note
- Yorkville convertible notes carry 8.75% interest (18% on default), mature Feb 2028, with initial conversion price of $1.5735/share and full-ratchet anti-dilution protection
- Company is non-compliant with Nasdaq's majority independent board and 3-member audit committee rules after director resignation on Aug 10, 2026; cure period ends Feb 6, 2027
- CEO Tim Johnson 2025 total comp: $814,880 (salary $420K + stock awards $394,880); CFO Julia Qian: $730,240 (salary $360K + stock $370,240)
- Insiders control 88.52% of total voting power (Class B shares carry 10 votes each)
- Audit fees declined to $425,300 in 2025 from $611,717 in 2024
Financial Impact
Potential dilution of up to 34.2M new shares (39% of current Class A outstanding) from SEPA alone, plus 10M new shares for equity plan; $6.65M already drawn from Yorkville with $8.35M more available in committed tranches
Risk Factors
- Massive dilution from 500M new authorized shares and up to 34.2M SEPA shares could depress stock price
- Yorkville convertible notes have full-ratchet anti-dilution protection, potentially forcing conversion at very low prices if stock declines
- Nasdaq non-compliance for independent board and audit committee could lead to delisting if not cured by Feb 2027
- Insider super-voting control (88.52% voting power) limits minority shareholder influence over governance
- Audit fees dropped 30% YoY despite increased complexity, potentially signaling resource constraints
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001213900-26-108738 |
| Document: 0001213900-26-108738-index-headers.html | 0001213900-26-108738 |
| Document: 0001213900-26-108738-index.html | 0001213900-26-108738 |
| Document: 0001213900-26-108738.txt | 0001213900-26-108738 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.5359 | awaiting T+60 | — | $0.5360 (+0.02%) |
Oct 22, 2026 4d ago | 3 | $0.5623 | awaiting T+60 | — | $0.5360 (−4.68%) |
Oct 16, 2026 10d ago | 8-K | $0.6350 | awaiting T+60 | — | $0.5360 (+15.59%) |
Oct 16, 2026 11d ago | EFFECT | $0.6520 | awaiting T+60 | — | $0.5360 (+17.79%) |
Oct 13, 2026 13d ago | DEF 14A | $0.6780 | awaiting T+60 | — | $0.5360 (+20.94%) |
Oct 9, 2026 17d ago | S-3/A | $0.7200 | awaiting T+60 | — | $0.5360 (+25.56%) |
Sep 30, 2026 26d ago | Press Release | $0.7380 | awaiting T+60 | — | $0.5360 (−27.37%) |
Sep 29, 2026 27d ago | SC 13G | $0.8525 | awaiting T+60 | — | $0.5360 (−37.13%) |
Sep 4, 2026 7w ago | S-3 | $0.9801 | awaiting T+60 | — | $0.5360 (+45.31%) |
Aug 13, 2026 10w ago | Press Release | $1.01 | awaiting T+60 | — | $0.5360 (+46.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers